Trivedi S, Potter-Lee L, McConville M W, Li J H, Ohnmacht C J, Trainor D A, Kau S T
Department of Pharmacology and Medicinal Chemistry Zeneca Pharmaceuticals Group, Zeneca Inc. Wilmington, DE 19897, USA.
Res Commun Mol Pathol Pharmacol. 1995 May;88(2):137-51.
Zeneca ZM244085, 9-(3 cyanophenyl)hexahydro-1,8 acridinedione, is a novel dihydropyridine (DHP) which relaxes KCl precontracted urinary bladder smooth muscle in vitro. The effect of ZM244085 on low and high KCl induced contractions, 86Rb efflux and [3H]-P1075 binding in guinea pig bladder strips was investigated to characterize the K-channel opening properties of this compound. Since ZM244085 is a dihydropyridine its effect on DHP binding sites on Ca2+ channels was also investigated. ZM244085 was found to be more potent in relaxing detrusor strips precontracted with 15 mM KCl than strips precontracted with 80 mM KCl (Li et al., 1995). This functional profile of ZM244085 is similar to that exhibited by typical K-channel openers (PCO). In addition, inhibition of ZM244085 induced relaxation of detrusor strips by glibenclamide suggests that ZM244085 opens ATP sensitive K-channel (KATP) in urinary bladder (Li et al., 1995). Since the glibenclamide sensitive smooth muscle relaxation activity of ZM244085 could still be an indirect effect of this compound on KATP channels we carried out 86Rb efflux studies and [3H]-P1075 binding studies to further confirm these findings. The 86Rb efflux assay is a direct method for monitoring the movement of K+ ions across the cell membranes. Displacement of [3H]-P1075 binding to bladder membranes supports a direct action of the compound on the KATP channel. The present study demonstrates that ZM244085 in a concentration dependent manner increases the rate of 86Rb efflux from guinea pig bladder strips. This effect was inhibited by glibenclamide (30 microM), a known KATP channel blocker. In addition, interaction of ZM244085 with KATP channels was also confirmed in human bladder smooth muscle cells using a 42K efflux assay. Furthermore, we were able to demonstrate that ZM244085, structurally distinct PCO, inhibited the binding of 3H-P1075 to urinary bladder strips in a manner similar to other KATP openers such as cromakalim and pinacidil. Inhibition of 3H-P1075 binding by ZM244085 and other PCO's correlates well with increases in 86Rb efflux and bladder muscle relaxation studies. Finally, ZM244085 did not exhibit any significant affect on VSCC as evidenced by very weak inhibition of [3H]-PN200,110 binding to bladder membranes by ZM244085. It is concluded that Zeneca ZM244085 is a PCO which activates KATP channels in urinary bladder.
捷利康公司的ZM244085,即9-(3-氰基苯基)六氢-1,8-吖啶二酮,是一种新型二氢吡啶(DHP),它在体外可使氯化钾预收缩的膀胱平滑肌松弛。研究了ZM244085对豚鼠膀胱条带中低浓度和高浓度氯化钾诱导的收缩、86Rb外流以及[3H]-P1075结合的影响,以表征该化合物的钾通道开放特性。由于ZM244085是一种二氢吡啶,因此还研究了其对钙通道上二氢吡啶结合位点的影响。已发现ZM244085在松弛由15 mM氯化钾预收缩的逼尿肌条带方面比由80 mM氯化钾预收缩的条带更有效(Li等人,1995年)。ZM244085的这种功能特性与典型的钾通道开放剂(PCO)所表现出的特性相似。此外,格列本脲对ZM244085诱导的逼尿肌条带松弛的抑制作用表明ZM244085可打开膀胱中的ATP敏感性钾通道(KATP)(Li等人,1995年)。由于ZM244085对格列本脲敏感的平滑肌松弛活性仍可能是该化合物对KATP通道的间接作用,我们进行了86Rb外流研究和[3H]-P1075结合研究以进一步证实这些发现。86Rb外流测定是监测钾离子跨细胞膜移动的直接方法。[3H]-P1075与膀胱膜结合的置换支持该化合物对KATP通道的直接作用。本研究表明,ZM244085以浓度依赖的方式增加豚鼠膀胱条带中86Rb的外流速率。这种作用被格列本脲(30 microM)抑制,格列本脲是一种已知的KATP通道阻滞剂。此外,使用42K外流测定法在人膀胱平滑肌细胞中也证实了ZM244085与KATP通道的相互作用。此外,我们能够证明,与结构不同的PCO相比,ZM244085以类似于其他KATP开放剂(如克罗卡林和吡那地尔)的方式抑制3H-P1075与膀胱条带的结合。ZM244085和其他PCO对3H-P1075结合的抑制作用与86Rb外流增加和膀胱肌肉松弛研究密切相关。最后,ZM244085对电压敏感性钙通道没有任何显著影响,这一点通过ZM244085对[3H]-PN200,110与膀胱膜结合的非常微弱的抑制作用得到证明。结论是,捷利康公司的ZM244085是一种PCO,可激活膀胱中的KATP通道。